Sionna Therapeutics Reports Positive Phase 1 Trial Results

Sionna Therapeutics, Inc. ( (SION) ) has provided an update.

On June 4, 2025, Sionna Therapeutics announced positive results from Phase 1 clinical trials for its NBD1 stabilizers, SION-719 and SION-451, which were well tolerated and met pharmacokinetic targets. These results support the potential of these compounds as add-ons to standard care or in proprietary dual combinations for cystic fibrosis treatment. Sionna plans to advance SION-719 to a Phase 2a trial in CF patients and SION-451 to a Phase 1 trial in healthy volunteers, with both trials set to begin in the second half of 2025 and topline data expected in mid-2026.

The most recent analyst rating on (SION) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Sionna Therapeutics, Inc. stock, see the SION Stock Forecast page.

More about Sionna Therapeutics, Inc.

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cystic fibrosis (CF) by normalizing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The company aims to improve clinical outcomes and quality of life for CF patients by stabilizing CFTR’s nucleotide-binding domain 1 (NBD1) and developing complementary CFTR modulators.

Average Trading Volume: 175,260

Current Market Cap: $616.4M

For an in-depth examination of SION stock, go to TipRanks’ Stock Analysis page.